Phase 1/2 study of XTX101, a masked, tumor-selective Fc-modified anti-CTLA4, in patients with advanced solid tumors.
- Resource Type
- Article
- Authors
- Davar, Diwakar; Knecht, John George; Vandross, Andrae Lavon; Perez, Cesar Augusto; Miller, David Michael; Powderly, John D.; Bessudo, Alberto; Patel, Ekta; Fantini, Damiano; Paramasivan, Sattanathan; Crowe, David; Duncan, Meghan; Uptain, Susan; Luptakova, Katarina; Sullivan, Ryan J.
- Source
- Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pe14685-e14685, 1p
- Subject
- Language
- ISSN
- 0732183X